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Metastatic melanoma was historically designated the ‘‘drug
killer cancer’’ because for decades no drug had demonstrated
any benefit in terms of overall survival (OS) for patients with
metastatic melanoma. This situation has radically changed
over the last 2 years. Melanoma appears today as a ‘‘pilot’’dis-
ease for which the most innovative therapeutic strategies
have demonstrated significant efficacy. The two strategies
are immunotherapy on the one hand and targeted therapy
on the other. These two significant breakthroughs led to the
authorisation in the United States (US) and in Europe of two
drugs: the anti-BRAF agent vemurafenib and the anti-CTLA-
4 monoclonal antibody ipilimumab. More recently, two addi-
tional targeted agents, dabrafenib and trametinib, were
authorised in the US. Moreover, the field continues to improve
with the exciting development of new drugs following these
two new approaches.
2. Immunotherapy: anti-CTLA-4 and
anti-PD-1
The anti-CTLA-4 monoclonal antibody ipilimumab was the
first drug ever to demonstrate a significant OS benefit in the
context of a randomised phase III trial [1]. This pivotal trial
showed that ipilimumab at the dose of 3 mg/kg, alone or in
combination with a peptidic vaccine and compared with vac-
cination alone, prolonged the survival of patients with pre-
treated metastatic melanoma. Median OS of patients was
around 10 months with ipilimumab versus 6.4 months with
the vaccination. A second pivotal trial evaluated ipilimumab
at 10 mg/kg, combined with the standard chemotherapy
dacarbazine (DTIC), compared with dacarbazine alone in
first-line treatment. The ipilimumab-containing arm demon-
strated a significant survival benefit compared with dacarba-
zine alone (HR = 0.72; P < 0.001) with a median OS of
11.2 months versus 9.1 [2]. This trial did not suggest that thecombination of DTIC with ipilimumab added any benefit,
but rather added toxicity, especially in terms of
hepatotoxicity.
Clinical results with ipilimumab are characterised by low
objective response rates, usually below 20%, but frequent
long-term responses. Responses are often delayed, being ob-
served after at least 4 months following initiation of therapy,
and can even occur after an initial tumour progression or the
appearance of new lesions.
As expected for a new mechanism of action, blocking
CTLA-4 is associated with a new spectrum of adverse events.
These are frequent, occurring in 40% of the patients and are
mostly immune-related, as expected for an immunostimula-
tory agent. The most frequent side effects are skin rashes,
diarrhoea and colitis resembling Crohn’s disease, hypophysi-
tis and hepatitis. Adverse effects usually resolve spontane-
ously or after steroid therapy. High-dose steroids have to be
prescribed in cases of severe immune-related adverse events;
rarely, stronger immunosuppressive agents, such as anti-
TNF-alpha (infliximab), can be needed.
Challenging questions remain to be answered to opti-
mise the efficacy of this new treatment. Indeed, the survival
benefit concerns few patients, and we currently lack predic-
tive clinical or biological markers of response. Furthermore,
the two pivotal trials have explored two different doses, 3 or
10 mg/kg, and two schedules of follow-up treatment de-
signs. Thus, the optimal administration schedule is still
unknown.
Programmed death-1 receptor (PD1) and its ligand (PD-L1)
are new, highly promising targets in immunotherapy. PD1
protein is another immune checkpoint expressed on many
T cells in response to inflammation. The engagement of PD1
on the lymphocyte surface by one of its ligands, PD-L1, that
can be expressed on melanoma cells, delivers inhibitory sig-
nals resulting in T-cell function down-regulation [3].
In contrast to CTLA-4/CD28 interaction that down-regu-
lates T-cell activation in lymphoid organs during naı¨ve T-cell2 11 42 10;
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exhaustion of T cells in peripheral tissues afterwards. Reacti-
vation of T cells that are already present on tumour sites is
thus an alternative and potentially complementary strategy
to improve cancer immunosurveillance.
Very compelling results of phase I trials evaluating two
anti-PD1 antibodies nivolumab and lambrolizumab were re-
cently published [4,5]. Various dose and schedule regimens
were evaluated in phase I trials. Response rates were around
30–40% for both antibodies, with the vast majority of respond-
ing patients still in response after median follow-up dura-
tions of more than 1 year. The safety profiles of these new
anti-PD-1 agents seem tolerable, with 10–12% of grade 3 or 4
adverse events, usually manageable except in rare cases of se-
vere pneumonitis.
Combined blockade of PD-1 and CTLA-4 has also been ex-
plored in a phase I trial in 86 patients, and also gave extre-
mely promising clinical results with tolerable adverse events
[6].
Combination of nivolumab and ipilimumab was associ-
ated with a 53% rate of treatment-related adverse effects that
most frequently corresponded to changes in biological
parameters (lipase, transaminase elevation) with no clinical
manifestation.3. The second strategy relies on the use of
targeted drugs: anti-BRAF and anti-MEK agents
BRAF and MEK are protein kinases involved in the MAP-kinase
pathway that is activated in the vast majority of melanomas
due to BRAF, NRAS, MEK and KIT mutations in (respectively)
about 50%, 15%, 8% and 3% of the cases [7].
Among BRAF mutations, the most frequent one – account-
ing for more than 90% of the somatic mutations of this onco-
gene – results in the V600E amino acid replacement.
Small kinase inhibitors directly targeting the mutated
BRAF protein have been developed. The first one, vemurafe-
nib, was recently approved as a first-line treatment for pa-
tients with unresectable or metastatic melanoma
harbouring the V600E BRAF mutation, based on the results
of a randomised phase III trial showing a significant improve-
ment in overall survival with vemurafenib (HR: 0.37, P < 0.001)
and a median progression-free survival (PFS) of 5.3 months
versus 1.6 months (HR: 0.26, P < 0.001) with dacarbazine and
a high response rate around 50% [8]. Dabrafenib, another
BRAF inhibitor, showed similar results in term of PFS and
objective response rate (ORR), but could not demonstrate OS
benefit because the design of the phase III trial included a
cross-over [9].
BRAF inhibitors are usually well tolerated, the most com-
mon adverse events being arthralgia (56% of the patients), fa-
tigue (46%) and cutaneous manifestations such as rash (41%),
photosensitivity (41% for vemurafenib only) and squamous-
cell carcinoma of the keratoacanthoma-type (10–25% of the
patients depending on the type of BRAF inhibitor used).
However, two major concerns are associated with all spe-
cific BRAF inhibitors evaluated so far. The most challenging
is the short median duration of the clinical responses, with
most of the patients relapsing in the 4–12 months after initi-ation of therapy. Numerous distinct resistance mechanisms
have been identified that can reactivate the MAPK pathway
(ERK-dependent) or use additional proliferation pathways
[10].
The second issue when using these agents is that they
paradoxically activate the MAPK pathway in cells devoid of
BRAF mutation, especially in the presence of an additional
somatic event occurring in this pathway, such as a RAS
mutation. This explains the appearance of squamous-cell
neoplasia (keratoacanthomas and squamous-cell carcino-
mas) as well as new melanomas in a subpopulation of pa-
tients [11].
One strategy to decrease secondary resistance as well as
neo-tumourigenesis associated with anti-BRAF monotherapy
is to combine it with an inhibitor of MEK1 and MEK2 down-
stream from BRAF. Indeed, several MEK blockers are in devel-
opment, and one of them, trametinib, has shown a
significantly increased PFS in patients with V600E metastatic
melanoma in a phase III randomised trial, and was recently
approved by the FDA [12]. Another MEK inhibitor, selumetinib,
also demonstrated an improvement in PFS when combined
with dacarbazine compared with dacarbazine plus placebo
in a randomised phase III trial [13]. Anti-MEK drugs are asso-
ciated with numerous skin side effects, as are most antican-
cer targeted agents, but potentially serious adverse events
involving the retina and myocardia are rare and mostly
reversible.
The most promising approach at present is the combina-
tion of BRAF and MEK inhibitors. Indeed, this approach not
only seems to give higher response rates and longer PFS but
is also associated with a significantly decreased incidence of
neo-skin-derived proliferation [14].4. Conclusion
A revolution in the metastatic melanoma treatment paradigm
is going on. We now have several effective weapons via both
the immunotherapy and the direct targeted therapy ap-
proaches. Our challenges are to optimise the design of treat-
ments in terms of combination and/or sequences and to
optimise safety regarding the new adverse events that are
occurring.
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